Category Archives: Psoriasis

PUBLIC RELEASE DATE:

27-Oct-2014

Contact: Tom Vasich tmvasich@uci.edu 949-824-6455 University of California - Irvine @UCIrvine

A UC Irvine-led study has revealed the underlying genetic factors that help repair skin lesions caused by psoriasis, which could engender new methods of controlling the lingering condition.

Dr. Bogi Andersen, professor of biological chemistry and endocrinology at UCI, and colleagues discovered that a gene called grainyhead known to be important in epidermal development and wound healing triggers a repair pathway for psoriasis lesions. Conversely, they found that deletion of this gene increased the severity and longevity of the disfiguring patches.

"Our research suggests that targeting this mechanism of healing may lead to pharmaceutical products that limit the itchy, painful lesions all psoriasis sufferers must endure," Andersen said. Study results appear online Oct. 27 in The Journal of Clinical Investigation.

Psoriasis is a chronic skin condition caused by an overactive immune system in which immune cells secrete inflammatory mediators that cause thickening and other abnormalities in the epidermis, the outermost layer of the skin. These lesions look like scaly plaques, and they heal at a rate dependent upon the severity of the disease.

The researchers learned that in psoriasis a compound called grainyhead-like 3 which binds to DNA to control the rate of transcription of genetic information from DNA to messenger RNA orchestrates the activation of an epidermal repair pathway. (The grainyhead gene was initially discovered in fruit flies, where it's important for wound healing.)

They also found it easier to induce psoriasis-like lesions in mice lacking the GRHL3 gene. Furthermore, these lesions did not resolve properly and persisted even in the face of active immune suppression treatments currently being studied for the disease.

"Our study indicates that an evolutionarily ancient epidermal repair pathway is activated in psoriasis lesions and that this pathway suppresses disease severity and helps heal the lesions," Andersen said. "We speculate that abnormalities in this pathway might contribute to disease severity and that in the future this mechanism could be targeted to help treat psoriasis."

Here is the original post:
UCI scientists identify lesion-healing mechanism in psoriasis

Skin PSA Video
Learn about psoriasis! Bibliography: Skin Anatomy. N.p., n.d. Web. 25 Oct. 2014. (http://dermatology.about.com/cs/skinanatomy/a/ anatomy.htm). Psoriasis Health Center. N.p., n.d. Web....

By: Pragnya Iyengar

See the rest here:
Skin PSA Video - Video

Diabetic foot, Psoriasis, mood disorder - Remedy Hospital in Hyderabad - 6TV Sanjeevani
6TV Sanjeevani is a special program to create awareness on diseases which leads to health problems disturbing daily life. The safety measures, remedies to be taken for the diseases and the...

By: 6tv

Here is the original post:
Diabetic foot, Psoriasis, mood disorder - Remedy Hospital in Hyderabad - 6TV Sanjeevani - Video

Psoriasis Revolution Review
Get Psoriasis Revolution: http://tinyurl.com/Psoriasis-Revolution-Review How To Permanently Stop Your Psoriasis, Eliminate red, inflamed itchy skin, silvery scales, burning or bleeding, Rebalance...

By: Psoriasis Revolution

See the original post here:
Psoriasis Revolution Review - Video

Novartis International AG / Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015

FDA Advisory Committee recommendation based on efficacy and safety outcomes of 10 Phase II/III clinical studies of secukinumab in moderate-to-severe plaque psoriasis

Affecting 7.5 million Americans, psoriasis may negatively impact daily life and is associated with increased risk for other chronic illnesses[1]-[3]

National Psoriasis Foundation survey of 5,600 patients found 52% were dissatisfied with their disease management[4]

Basel, 20 October, 2014 - Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) today voted unanimously to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy). The DODAC based its recommendation on the safety and efficacy outcomes from 10 psoriasis Phase II/III clinical studies which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.

"Moderate-to-severe psoriasis is a serious condition where patients suffer from skin lesions that cause itching, pain and scaling. There is a need for novel therapies as not all treatments are appropriate or effective in every patient," said Vas Narasimhan, Global Head Development, Novartis Pharmaceuticals. "Today's recommendation is based on the efficacy and safety data put forth in our robust clinical trial program and brings us one step closer to delivering an innovative, new treatment option for people suffering from moderate-to-severe psoriasis. We look forward to working with the FDA as it finalizes its review."

The Phase III clinical program for secukinumab included four placebo-controlled pivotal studies which examined secukinumab 300 mg and 150 mg in patients with moderate-to-severe plaque psoriasis. In these studies, secukinumab met all primary and key secondary endpoints, including Psoriasis Area and Severity Index (PASI) 75 and 90 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 responses, showing significant skin clearance at Week 12[5]-[7]. In addition, a majority of secukinumab-treated patients who achieved PASI 75 response and IGA mod 2011 0/1 at Week 12 maintained the response at Week 52 with continued treatment[7]. PASI measures the redness, scaling and thickness of psoriatic plaques, and the extent of involvement in each region of the body[8]. Treatment efficacy is assessed by the reduction of the score from baseline (i.e., a 75% reduction is known as PASI 75 and a 90% reduction is known as PASI 90). PASI 90 is a higher standard of skin clearance compared to PASI 75[8].

Currently available data showed no major safety issues. In the pooled analysis of the placebo-controlled period of the pivotal Phase III studies, the incidence of serious adverse events (SAEs) was low and comparable for both doses of secukinumab and placebo (2.0% for both 300 mg and 150 mg vs. 1.7% for placebo)[5]-[7]. Commonly reported adverse events (AEs) observed with secukinumab were nasopharyngitis, headache, diarrhea, pruritus (itching), and upper respiratory infection[5]-[7].

Novartis submitted a Biologics License Application (BLA) for secukinumab to the FDA in October 2013 and the FDA action date is expected in early 2015. Additionally, submissions have been made with regulatory authorities in the EU with an expected decision anticipated in late 2014 or early 2015.

The rest is here:
Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with ...

DermaMed Psoriasis Kit - Rescue Balm and Nutrition for Troubled Skin
http://www.biologicalhealthgroup.com/product/dermamed-psoriasis-kit/ Provides a focused, two-step support program for managing psoriasis. Contains a powerful...

By: PDC BiologicalHealthGroup

Read more:
DermaMed Psoriasis Kit - Rescue Balm and Nutrition for Troubled Skin - Video

PBR Staff Writer Published 21 October 2014

The US Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) has approved Novartis' AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, to treat moderate-to-severe plaque psoriasis in adult patients.

The DODAC recommendation is based on the safety and efficacy outcomes from ten psoriasis Phase II/III clinical trials which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.

Novartis Pharmaceuticals global head development Vas Narasimhan said moderate-to-severe psoriasis is a serious condition where patients suffer from skin lesions that cause itching, pain and scaling.

"There is a need for novel therapies as not all treatments are appropriate or effective in every patient," Narasimhan said.

"Today's recommendation is based on the efficacy and safety data put forth in our robust clinical trial program and brings us one step closer to delivering an innovative, new treatment option for people suffering from moderate-to-severe psoriasis. We look forward to working with the FDA as it finalizes its review."

The Phase III clinical program for secukinumab included four placebo-controlled pivotal trials which examined secukinumab 300mg and 150mg in patients with moderate-to-severe plaque psoriasis.

In these studies, secukinumab met all primary and key secondary endpoints, including Psoriasis Area and Severity Index (PASI) 75 and 90 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 responses, showing significant skin clearance at Week 12.

The company submitted a Biologics License Application (BLA) for secukinumab to the FDA in October 2013 and the FDA action date is expected in early 2015.

See original here:
Novartis' plaque psoriasis drug candidate AIN457 gets FDA committee recommendation

Psoriasis Diet Diary Week Four
This weeks video includes a new resource to look at, stay strong!

By: Jon Maddison

See original here:
Psoriasis Diet Diary Week Four - Video

Autoimmune form of Pneumonia is related to Psoriasis Inflammation #41
Autoimmune inflammatory sensitivity sometimes causes a form of pneumonia. Autoimmune pneumonia and psoriasis have the same cause;eating toxic foods like vinegar your family heritage never ate.

By: Psoriasis Channel

Read more from the original source:
Autoimmune form of Pneumonia is related to Psoriasis & Inflammation #41 - Video

"It #39; alright sis"!
Psoriasis is a chronic autoimmune disease that causes red, scaly patches to appear on the skin. It affects between 1 and 2 percent of the Singaporean population. In addition to intense itching...

By: Dr Jiajia BigBro #39;s Show

Read the original:
"It' alright sis"! - Video